Lind Precision Trial Matching Platform

Lind is an intelligent research platform for health systems that matches patients to clinical trials; a May 2026 article describes it as a US-based company. The website does not state a founding year or headquarters.

The platform pre-screens patients criterion by criterion with evidence pulled from the chart, scores trial-arm matches inside the EHR, flags missing evidence and keeps clinicians in the loop. Sponsors get site selection, patient density and per-criterion eligibility insights. It is FHIR-native and data-source agnostic.

• Criterion-level pre-screening: evidence from the chart for each criterion.
• Trial-arm match scoring: embedded in the EHR.
• Evidence gaps: highlights missing evidence and evidence of absence.
• Clinician review: human check before enrollment decisions.
• Sponsor tools: site selection, patient density and eligibility insights.
• Molecular profiling: Lind Asia adds genomic and proteomic data for biomarker-driven matching.

Vietnamese cancer hospitals with EHR systems could pre-screen patients for international biomarker-driven trials. Pharma sponsors could use patient density data to pick sites in Southeast Asia.

Pre-screens with evidence tied to the patient chart. Embeds match scores in the EHR workflow. Keeps clinician review where judgment is needed. Gives sponsors site and eligibility insights. Site lists HIPAA compliance and SOC 2 certification.

Health systems in Asia-Pacific are adopting AI screening to cut screen failures in biomarker-driven oncology trials. Vietnam's large hospitals may follow as genomic testing and EHR adoption grow.

2026-05: joint venture Lind Asia with PREMIA, exclusive regional partner for Taiwan, Japan, South Korea, Singapore and Australia (BioSpectrum Asia, 2026-05-29). Partner Advocate Health named on site.